NASDAQ:CERE Cerevel Therapeutics (CERE) Stock Price, News & Analysis → The 'Smart Money' Is Ready for May 1st Are You? (From Stansberry Research) (Ad) Free CERE Stock Alerts $41.90 -0.09 (-0.21%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$41.87▼$42.0650-Day Range$40.88▼$42.9352-Week Range$19.59▼$43.59Volume629,646 shsAverage Volume1.49 million shsMarket Capitalization$7.61 billionP/E RatioN/ADividend YieldN/APrice Target$41.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial Media Get Cerevel Therapeutics alerts: Email Address Cerevel Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.20 Rating ScoreUpside/Downside1.2% Downside$41.40 Price TargetShort InterestBearish11.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.62Based on 7 Articles This WeekInsider TradingSelling Shares$4.30 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.53) to ($2.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.21 out of 5 starsMedical Sector886th out of 909 stocksPharmaceutical Preparations Industry415th out of 423 stocks 1.1 Analyst's Opinion Consensus RatingCerevel Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageCerevel Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.06% of the float of Cerevel Therapeutics has been sold short.Short Interest Ratio / Days to CoverCerevel Therapeutics has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Cerevel Therapeutics has recently increased by 38.22%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCerevel Therapeutics does not currently pay a dividend.Dividend GrowthCerevel Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CERE. Previous Next 3.1 News and Social Media Coverage News SentimentCerevel Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Cerevel Therapeutics this week, compared to 3 articles on an average week.Search Interest1 people have searched for CERE on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Cerevel Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cerevel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,302,367.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of Cerevel Therapeutics is held by insiders.Percentage Held by Institutions87.73% of the stock of Cerevel Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cerevel Therapeutics are expected to decrease in the coming year, from ($2.53) to ($2.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cerevel Therapeutics is -16.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cerevel Therapeutics is -16.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCerevel Therapeutics has a P/B Ratio of 11.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThe system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About Cerevel Therapeutics Stock (NASDAQ:CERE)Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.Read More CERE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CERE Stock News HeadlinesApril 22, 2024 | markets.businessinsider.comHold Rating Maintained for Cerevel Post-Positive Phase 3 Data Amid Pending AbbVie AcquisitionApril 18, 2024 | benzinga.comSoon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease StudyApril 24, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.April 18, 2024 | msn.comAbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drugApril 18, 2024 | reuters.comCerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage studyApril 18, 2024 | finance.yahoo.comCerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s DiseaseApril 18, 2024 | globenewswire.comCerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's DiseaseApril 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Unity Biotechnology (UBX)April 24, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 12, 2024 | seekingalpha.comAbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67%April 5, 2024 | investing.comCerevel Therapeutics director sells $2.12m in stock, buys $175k worthApril 3, 2024 | uk.finance.yahoo.comDirector N Coles Sells 50,000 Shares of Cerevel Therapeutics Holdings Inc (CERE)March 29, 2024 | wsj.comCerevel Therapeutics Holdings Inc.March 29, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Apellis Pharmaceuticals (APLS)March 16, 2024 | finance.yahoo.comCERE Apr 2024 40.000 callMarch 7, 2024 | markets.businessinsider.comCerevel Therapeutics: Hold Rating Amidst Pending AbbVie AcquisitionMarch 6, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Perspective Therapeutics (CATX)March 6, 2024 | seekingalpha.comCerevel Therapeutics: Parkinson's Could Be The IssueFebruary 28, 2024 | markets.businessinsider.comMaintaining Hold Rating Amid ABBV-CERE Deal Progress and Rising Operational CostsFebruary 24, 2024 | uk.finance.yahoo.comABBV Mar 2024 182.500 callFebruary 23, 2024 | bloomberg.comUS Politicians Raise Concerns Over Capital One-Discover DealFebruary 23, 2024 | uk.finance.yahoo.com3M Healthcare Unit Solventum Joins $53 Billion US Corporate Bond Sales SpreeFebruary 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Intra-Cellular Therapies (ITCI)February 22, 2024 | finance.yahoo.comAbbVie Selling $15 Billion Bonds to Buy ImmunoGen, CerevelFebruary 21, 2024 | reuters.comAbbVie eyes selling at least $13 bln of bonds to fund M&A, Bloomberg reportsFebruary 21, 2024 | finance.yahoo.comAbbVie (ABBV) Announces Appointment of New CEO Robert MichaelFebruary 16, 2024 | seekingalpha.comWall Street Breakfast Podcast: OpenAI's Text-To-Video AI ModelSee More Headlines Receive CERE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2023Today4/24/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryCoal & Consumable Fuels Current SymbolNASDAQ:CERE CUSIP15677310 CIK767884 Webceres.net Phone844-304-2048FaxN/AEmployees334Year FoundedN/APrice Target and Rating Average Stock Price Target$41.40 High Stock Price Target$45.00 Low Stock Price Target$30.00 Potential Upside/Downside-1.2%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-432,840,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-100.14% Return on Assets-44.51% Debt Debt-to-Equity Ratio0.50 Current Ratio10.92 Quick Ratio10.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.71 per share Price / Book11.29Miscellaneous Outstanding Shares181,580,000Free Float172,316,000Market Cap$7.61 billion OptionableOptionable Beta1.48 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. N. Anthony Coles Jr. (Age 64)M.P.H., Executive Chairman Comp: $1.14MMr. Mark Bodenrader (Age 51)VP of Finance & Chief Accounting Officer Comp: $496.17kDr. John J. Renger Ph.D. (Age 55)Chief Scientific Officer Comp: $779.75kDr. Ramiro Sanchez M.D. (Age 63)Chief Medical Officer Comp: $805.13kMr. Ronald C. Renaud Jr. (Age 55)M.B.A., President, CEO & Director Dr. Susan Altschuller M.B.A. (Age 42)Ph.D., Chief Financial Officer Mr. Matthew CalistriVice President of Investor RelationsMr. Scott M. Akamine J.D. (Age 39)Chief Legal Officer & Corporate Secretary Comp: $444.74kMr. Kenneth A. DiPietro (Age 65)Chief Human Resources Officer Ms. Kathleen Tregoning M.A. (Age 53)Chief Corporate Affairs Officer Comp: $600.79kMore ExecutivesKey CompetitorsIntra-Cellular TherapiesNASDAQ:ITCIViking TherapeuticsNASDAQ:VKTXJazz PharmaceuticalsNASDAQ:JAZZCytokineticsNASDAQ:CYTKAscendis Pharma A/SNASDAQ:ASNDView All CompetitorsInsiders & InstitutionsKapitalo Investimentos LtdaBought 180,000 shares on 3/29/2024Ownership: 0.099%PNC Financial Services Group Inc.Sold 3,006 shares on 3/22/2024Ownership: 0.004%Vanguard Group Inc.Bought 1,003,594 shares on 3/11/2024Ownership: 4.062%Wellington Management Group LLPSold 12,182 shares on 3/5/2024Ownership: 0.020%N Anthony ColesSold 50,000 sharesTotal: $2.05 M ($41.01/share)View All Insider TransactionsView All Institutional Transactions CERE Stock Analysis - Frequently Asked Questions Should I buy or sell Cerevel Therapeutics stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerevel Therapeutics in the last year. There are currently 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CERE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERE, but not buy additional shares or sell existing shares. View CERE analyst ratings or view top-rated stocks. What is Cerevel Therapeutics' stock price target for 2024? 10 Wall Street research analysts have issued 1-year price targets for Cerevel Therapeutics' stock. Their CERE share price targets range from $30.00 to $45.00. On average, they predict the company's stock price to reach $41.40 in the next twelve months. This suggests that the stock has a possible downside of 1.2%. View analysts price targets for CERE or view top-rated stocks among Wall Street analysts. How have CERE shares performed in 2024? Cerevel Therapeutics' stock was trading at $42.40 at the beginning of 2024. Since then, CERE shares have decreased by 1.2% and is now trading at $41.90. View the best growth stocks for 2024 here. Are investors shorting Cerevel Therapeutics? Cerevel Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 9,620,000 shares, an increase of 38.2% from the March 15th total of 6,960,000 shares. Based on an average trading volume of 1,510,000 shares, the short-interest ratio is currently 6.4 days. Approximately 11.1% of the company's stock are short sold. View Cerevel Therapeutics' Short Interest. When is Cerevel Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our CERE earnings forecast. How were Cerevel Therapeutics' earnings last quarter? Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) released its quarterly earnings data on Wednesday, November, 1st. The biotechnology company reported ($0.61) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.63) by $0.02. During the same period last year, the company posted ($0.66) earnings per share. What ETFs hold Cerevel Therapeutics' stock? ETFs with the largest weight of Cerevel Therapeutics (NASDAQ:CERE) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), First Trust Merger Arbitrage ETF (MARB), IQ Merger Arbitrage ETF (MNA), AltShares Event-Driven ET (EVNT), AltShares Merger Arbitrage ETF (ARB), ProShares Merger ETF (MRGR) and Principal Healthcare Innovators ETF (BTEC). What other stocks do shareholders of Cerevel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cerevel Therapeutics investors own include Precigen (PGEN), Arena Pharmaceuticals (ARNA), CTI BioPharma (CTIC), Achillion Pharmaceuticals (ACHN), Alpha Natural Resources (ANRZQ), Cenveo (CVO), Hess (HES), Palatin Technologies (PTN), Aeterna Zentaris (AEZS) and Avid Bioservices (CDMO). How do I buy shares of Cerevel Therapeutics? Shares of CERE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CERE) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerevel Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
